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Table 1
Number of DRG neurons responding to physical stimuli at 8 weeks post surgery.
mean±SEM
100g paw pinch 30g knee pinch 60 knee twist
Sham (n¼2) 1.0±0.0 5.5±2.5 7.0±5.0
DMM (n¼4) 8.8±2.3 31.6±22.1 20.8±4.1
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A6172.0±12.9kg) who participated in a baseline biomechanical assessment
upon enrollment in this investigation. An electromagnetic tracking
system interfaced with a force plate was used to collect three-dimen-
sional kinematics of the hip and knee during three trials of a jump-
landing task. Following the baseline biomechanical assessment, par-
ticipants were followed prospectively through a closed healthcare
system for a maximum of four years to identify those diagnosed with
PFP. Incident cases of PFP were initially identiﬁed through electronic
injury surveillance systems speciﬁc to the study population and
determined by a manual review of medical records. The inclusion cri-
teria for the incident PFP group included: retropatellar knee pain with
physical activity, pain on palpation of either the patellar facets or
femoral condyles, and negative ﬁndings on examination for injury to
the knee ligaments, menisci, bursae, and synovial plica. Sagittal, frontal,
and transverse plane hip and knee kinematics during the jump-landing
task at initial contact (IC) with the ground, and at the time of maximum
knee ﬂexion (approximately mid-point of the task) were included in the
data analysis. Separate logistic regression analyses were performed to
determine the inﬂuence of each biomechanical variable on the risk of
developing PFP (P<0.05).
Results: Of the 4418 participants who initially enrolled in this inves-
tigation, 493 participants reported a prior history of PFP and were
removed from the cohort used in the ﬁnal analysis. During the follow up
period, 188 participants (94 females, 94 males) were diagnosed with
incident PFP. Greater knee ﬂexion at IC (>20 vs. <20) was associated
with a reduced risk of developing PFP [Odds Ratio (OR)¼0.69, 95%
Conﬁdence Interval (CI)¼0.49,0.99]. Less hip abduction at IC (<10 vs.
>10) was associated with an increased risk of developing PFP
(OR¼1.72, 95% CI¼1.17, 2.51). No other kinematic variables were asso-
ciated with the development of PFP (P>0.05).
Conclusions: Sagittal plane kinematics at the knee along with frontal
plane kinematics at the hip appear to have a signiﬁcant inﬂuence on the
risk of developing PFP. These movement characteristics may be altered
through movement retraining programs focused on primary injury
prevention. These programs should focus on greater knee ﬂexion and a
wider stance during jumping and landing activities. Additional research
is needed to determine if injury prevention programs are effective in
reducing the incidence of PFP and the subsequent risk of injury related
KOA.
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IN VIVO CALCIUM IMAGING OF KNEE-INNERVATING DORSAL ROOT
GANGLION NEURONS REVEALS INCREASED NEURONAL
RESPONSIVENESS TO PHYSICAL STIMULI AFTER DMM SURGERY
R.E. Miller y, K. Park z, S. Ishihara y, Y. Kim z, R.J. Miller x, X. Dong z,
A.-M. Malfait y. yRush Univ. Med. Ctr., Chicago, IL, USA; z Johns Hopkins
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Purpose: Osteoarthritis pain is typically brought on by movement, yet
there are limited techniques for studying the ability of speciﬁc move-
ments to activate neurons. Our previous work has shown that after
destabilization of the medial meniscus (DMM), mice develop slowly
progressive joint damage concurrent with the following pain-related
behaviors: hindpaw mechanical allodynia, knee hyperalgesia and
locomotive deﬁcits.
In vivo electrophysiology enables monitoring of action potentials in
single neurons while physical stimuli are applied to the knee, but a
technique to visualize concerted responses of neurons within the dorsal
root ganglion (DRG) has not been available. Here, we utilized a new
method for imaging intracellular calcium ((Ca)i) responses by DRG
neurons in vivo, while physical stimuli are applied to the hindlimb, in
order to determine how neuronal responses change after DMM surgery.
Methods: DMM (n¼4) or sham (n¼2) surgery was performed in 10-
week old male, heterozygous Pirt-GCaMP3 mice on a C57BL/6 back-
ground. These mice express the ﬂuorescent calcium indicator, GCaMP3,
in ~90% of all sensory DRG neurons, and not in other peripheral or
central tissues, through the Pirt promoter. Eight weeks after surgery,
mice were deeply anesthethized using sodium pentobarbital, and the
back and operated knee were shaved. A laminectomy from vertebrae
L2-L6 was performed, and the L4 DRG exposed. The mouse was posi-
tioned under a Leica LSI confocal and camera system by clamping the
spinal column at L2 and L6 using forceps attached to micro-
manipulators. Anesthesia was maintained using isoﬂuorane during
imaging and temperature was maintained using a homeothermic
blanket system. Physical stimuli to the ipsilateral limb included: 1. A100g force was applied to the hindpaw using a calibrated forceps sys-
tem (IITC Rodent Pincher); 2. A 30g force was applied to the knee using
the same calibrated forceps system; 3. A noxious rotation (~60 , which
is beyond the normal physiological range) was applied to the knee. For
each stimulus, imaging was started one minute prior to the application
of the stimulus, continued while the stimulus was applied, and was
stopped one minute after the stimulus was discontinued. Each 200
frame video was analyzed for numbers of neurons responding during
the applied stimulus. It was assumed that similar total numbers of
neurons were imaged during each experiment. At the end of each
experiment, mice were sacriﬁced to ascertain that these mice devel-
oped similar joint damage as wild-type C57BL/6 mice.
Results: Eight weeks after DMM or sham surgery, we began by applying
a 100g pinch to the ipsilateral hindpaw. This stimulus induced (Ca)i
increases in somewhat greater numbers of neurons in DMM mice
compared to sham mice (Table 1).
In contrast, when forces were applied directly to the operated knee,
there were clear differences in (Ca)i responses seen in DRG neurons in
DMM mice compared to sham DRG neurons. More neurons responded
to a 30g pinch, as well as to a noxious (60) twist applied to the operated
knee in DMM mice, compared to sham mice (Table 1).
Conclusions: In this pilot experiment, we demonstrated that DRG
neurons in mice that have undergone DMM surgery are more respon-
sive to physical stimuli directed toward the operated knee compared to
sham mice, matching well with pain-related behaviors. It is likely that
increased (Ca)i reﬂects increased excitability of this neuronal pop-
ulation. Future work will be directed at using this technique to identify
which subsets of neurons respond to these stimuli and to monitor how
these neuronal responses change longitudinally over the course of the
DMM model.
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RELATION OF SMOKING TO WIDESPREAD PAIN, KNEE PAIN
SEVERITY, AND PAIN SENSITIZATION: THE MULTICENTER
OSTEOARTHRITIS (MOST) STUDY
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yBoston Univ. Sch. of Med., Boston, MA, USA; zUniv. of Iowa at Iowa
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Purpose: Smokers have been reported to have more musculoskeletal
pain compared with nonsmokers. Whether this is the case for knee
osteoarthritis (OA) pain or rather widespread pain is not known,
and, if present, the mechanism of increased pain among smokers is
not clear. Pain sensitization among smokers might explain their
increased risk of musculoskeletal pain. We used data from the
Multicenter Osteoarthritis (MOST) Study to examine the relation of
smoking to widespread pain, knee pain severity, and pain
sensitization.
Methods: The MOST Study recruited 3,026 subjects with or at risk for
knee OA at baseline. Cigarette smoking status (never, former, current
smoker), smoking intensity (in pack-years), knee-speciﬁc WOMAC
pain subscale, and pain, aching, or stiffness of each joint on most days
marked on a joint pain homunculus were asked at baseline and the
84-month visit. Widespread pain (WSP) was deﬁned using ACR cri-
teria. Incident WSP was deﬁned as development of WSP during 84-
month follow-up among subjects without WSP at baseline. Pain
sensitization was examined at the 84 month visit. Knee pain severity
was assessed with the knee-speciﬁc WOMAC pain subscale. Temporal
summation (TS) at the right wrist was measured by application of a
60g von Frey monoﬁlament repeatedly (30 x1Hz), and deﬁned as
being present if there was an increase in pain rating at the end of the
train. Pressure pain threshold (PPT) at the right wrist was measured
using a pressure algometer applied with steadily increasing pressure
and recordings were taken at the ﬁrst sensation of slight pain. We
Table
Relation of smoking status and intensity to widespread pain and knee pain severity.
Widespread pain at baseline Incident widespread pain at 84-month visit Knee pain severity (WOMAC) at baseline
N(%) of knees Adjusted OR* (95% CI) N(%) of knees Adjusted OR* (95% CI) N of knees Adjusted difference in
median* (95% CI)
Smoking status
never smoker 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
current smoker 106/195 (54.4) 1.0 (0.7, 1.5) 12/53 (22.6) 0.9 (0.4, 2.0) 196 0.83 (0.03, 1.63)
former smoker 596/1147 (52.0) 1.3 (1.0, 1.5)1 92/400 (23.0) 1.2 (0.9, 1.7) 1154 0.00 (0.25, 0.25)
Smoking intensity (pack-year)
0 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
1-10 251/495 (50.7) 1.2 (0.9, 1.5) 36/191 (18.8) 0.9 (0.6, 1.4) 497 0.33 (0.04, 0.70)
10-29 250/481 (52.0) 1.3 (1.0, 1.6)1 38/158 (24.1) 1.3 (0.8, 2.0) 484 0.17 (0.22, 0.56)
301 201/365 (55.1) 1.2 (0.9, 1.6) 30/103 (29.1) 1.7 (1.0, 2.8) 369 0.00 (0.43, 0.43)
*Adjusting for age. sex, race, clinic, BMI, Kellgren and Lawrence grade, CES-D score, and catastrophizing; p<0.0l
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at baseline using logistic regression, and between smoking and knee
pain severity at baseline using quantile regression with generalized
estimating equations to account for correlations between two knees
within a subject. We used the same approach to assess the effect of
baseline smoking on incident WSP. For pain sensitization outcomes,
we used logistic regression to assess the cross-sectional relation
between smoking and TS at 84-month visit, and used linear regres-
sion to assess the relation between smoking and PPT. Age, sex, race,
clinic, BMI, Kellgren and Lawrence grade of radiographic OA severity,
CES-D score, and catastrophizing were adjusted for as potential
confounders.
Results: Among 3026 subjects recruited at baseline (age mean ±; SD:
62.5 ±; 8.1, BMI mean ±; SD: 30.7 ±; 6.0 kg/m2, 60% women), 197
subjects (6.5%) were current smokers and 1155 (38.2%) were former
smokers. The median (25th, 75th percentile) smoking intensity among
smokers was 21.5 (15.0, 31.0) pack-years. The prevalence of WSP at
baseline were 50%, 55%, and 52% among never smokers, current
smokers and former smokers, with slightly higher prevalence among
former smokers compared with non-smokers (adjusted odds ratio
(95% CI) ¼ 1.3 (1.0, 1.5), p¼0.01). The risk of incident WSP at the 84-
month follow-up was similar among the three smoking status groups
(Table). While the prevalence of WSP at baseline did not differ by
smoking intensity, the risk of incident WSP increased with increasing
smoking intensity; smokers with 1-9, 10-29, 30 pack-years had odds
ratios of 0.9, 1.3 and 1.7, respectively, for risk of incident WSP com-
pared with non-smokers (p-value for linear trend ¼0.02). Knee pain
severity was higher among current smokers than non-smokers (Table),
but there was no relation to smoking intensity. The prevalence of TS at
84-month visit was 39%, and did not differ by smoking status or
intensity. Similarly, there was no difference in PPT by smoking status
or intensity.
Conclusions: Smoking intensity had a dose response relationship with
incident WSP, and current smoking was associated with knee pain
severity. No relation was observed between smoking and pain sensiti-
zation. The reasons for increased pain among smokers need further
clariﬁcation.
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TGF-b IS A POTENT INDUCER OF NERVE GROWTH FACTOR IN
ARTICULAR CARTILAGE VIA THE ALK5-SMAD2/3 PATHWAY.
POTENTIAL ROLE IN OA RELATED PAIN?
E. N. Blaney Davidson, A.P. van Caam, E.L. Vitters, M.B. Bennink,
E. Thijssen, W.B. van den Berg, M.I. Koenders, P.L. van Lent,
F.A. van de Loo, P.M. van der Kraan. Radboud Univ. Med. Ctr., Nijmegen,
Netherlands
Purpose: Pain is the main problem for patients with OA. Unfortunately,
pain relief is not effective in every individual. In general, pain is linked
to inﬂammation. However, in a subset of OA patients pain is experi-
enced without obvious inﬂammation driving the pain. This indicates
there must be an additional alternative source of pain besides inﬂam-
mation. NGF inhibition has been shown very efﬁcient in blocking pain
during OA, but the exact source of NGF is unclear. NGF is elevated in
human OA,as well as in animal models of OA with cartilage damage
without inﬂammation.TGF-beta is released from cartilage upondamage. We investigated whether TGF-beta could contribute to NGF
expression in the joint. Furthermore, we studied the speciﬁc Smad-
related TGF-beta pathways involved in this process.
Methods:Murine andhuman chondrocyte cell lines, primarybovine and
human chondrocytes, and cartilage explants from bovine metacarpal
joints and humanOA jointswere stimulatedwith TGF-b1 and/or IL-1b as
a positive control for NGF induction. We analyzed NGF expression on
mRNA level with QPCR and stained human OA cartilage for NGF immu-
nohistochemically. Cultures were additionally pre-incubated with
inhibitors for TAK1 (oxozeaenol), Smad2/3 (SB-505124) or Smad1/5/8
(LDN-193189) signaling to identify the TGF-b pathway inducing NGF.
Results: We found that TGF-beta was capable of inducing NGF
expression, even in low dosage of 1 ng/ml. NGF expression was con-
sistently induced at higher levels by TGF-b than IL-1 in all of our
experiments: murine, bovine and human origin, in cell lines, primary
chondrocytes and explants cultures. Combining TGF-beta with IL-1 did
not result in higher levels of NGF expression than those already reached
by a single dose of TGF-beta alone. As TAK1 is a common pathway
component of both IL-1 and TGF-beta signaling, we initially expected
TAK1 to be dominant and pivotal in NGF induction. TAK1 inhibition
consistently reduced (but not blocked) TGF-b-induced NGF whereas it
fully blocked IL-1b-induced NGF expression. In contrast, ALK5-Smad2/3
inhibition fully blocked TGF-b-induced NGF expression. Blocking the
Smad1/5/8 pathway with LDN did not have an effect on TGF-beta-
induced NGF. In human OA primary chondrocytes we found that there
was a large variation in basal NGF levels (mRNA and histology). Upon
stimulation with TGF-b we found a consistent higher level of NGF
induction than upon stimulationwith IL-1, which was not related to the
basal levels of NGF. In explants of human OA cartilage we observed
chondrocytes positive staining for NGF. When stimulating human OA
cartilage with TGF-beta NGF expression increased, which could be fully
blocked by inhibiting ALK5-Smad2/3 signaling.
Conclusions: This is the ﬁrst time that it is shown that TGF-b induces
NGF expression in (primary) chondrocytes. Moreover, we found that
TGF-beta consistently induced NGF at higher levels than IL-1. In addi-
tion, IL-1 induced NGF could be fully abrogated by TAK1 inhibition, but
this only had a reducing effect on TGF-beta induced NGF expression. In
contrast blocking signaling via ALK5-Smad2/3 fully abrogated the TGF-
beta-induced NGF expression. Clearly, our data show that there are
sources of NGF other than inﬂammation in the joint and that this should
be taken into account when studying pain in OA.
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CITED2 MEDIATES CROSS-TALK BETWEEN MECHANICAL LOADING
AND IL-4 AND RESULTS IN SYNERGISTIC CHONDROPROTECTION IN
VITRO AND IN VIVO
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Purpose: Interleukin (IL)-4, is an anti-inﬂammatory cytokine that
reduces pro-inﬂammatory cytokine production and activity, and might
be chondroprotective. However clinical trials using IL-4 have not been
successful due to side effects from high doses of IL-4. CITED2 (CBP/
P300-interacting transactivator 2), originally identiﬁed as an IL-4-
